DASTON [Sodium Creatine Phosphate] 1 g Powder for intravenous solution

DASTON

instructions for medical use of the medicinal product

Tradename

Daston, Daston

International non-proprietary name

Phosphocreatine, Phosphocreatine

Composition

Each vial (50 ml) contains:

active substance: sodium creatine phosphate 1 g

Dosage form

Powder for solution for infusion.

Pharmacotherapeutic group

metabolic agent .

Pharmacological properties

Daston is a drug that improves the metabolism of the myocardium and muscle tissue.

Pharmacodynamics

Phosphocreatine plays an important role in the energy mechanism of muscle contraction. The chemical structure is similar to macroergic endogenous phosphocreatine. It inhibits the process of destruction of the sarcolemma of ischemic cardiomyocytes and myocytes, provides intracellular energy transport. By improving microcirculation, the drug reduces the size of the zone of necrosis and ischemia. In ischemia and postischemic reperfusion, it has an antiarrhythmic effect, which is associated with a decrease in the ectopic activity of the ventricles and the preservation of the physiological function of Purkinje fiber cells.

Pharmacokinetics

With a single intravenous infusion, the maximum concentration of the drug in the blood plasma is determined for 1-3 minutes. The largest amount of the drug accumulates in the skeletal muscles, myocardium and brain. In the tissues of the liver and lungs, the accumulation of the drug is insignificant.
The half-life in the fast phase is 30-35 minutes. The half-life in the slow phase is several hours. Excreted by the kidneys.

Indications for use

In complex therapy:

·        acute myocardial infarction;

·        chronic heart failure;

·        intraoperative myocardial ischemia;

·        intraoperative limb ischemia;

·        acute cerebrovascular accident;

·        in sports medicine: to prevent the development of the syndrome of physical overstrain and improve adaptation to extreme physical exertion.

Contraindications

·        hypersensitivity to the drug ;

·        chronic renal failure (for use in doses of 5-10 g / day);

·        age up to 18 years (efficacy and safety have not been established).

Dosage and administration

In acute myocardial infarction , on the 1st day, 2-4 g is injected intravenously, followed by a drip infusion of 8-16 g in 200 ml of 5% glucose solution for 2 hours. On the 2nd day: 2-4 g in / in drip 2 times / day. Day 3: 2 g intravenously 2 times a day. If necessary, a course of infusions of the drug 2 g 2 times / day can be carried out for 6 days. In chronic heart failure, it is administered intravenously at a dose of 1-2 g 2 times / day for 10-14 days.

In case of intraoperative myocardial ischemia, the drug is administered as part of a conventional cardioplegic solution in an amount of 3 g per 1 liter. Duston is added to the composition of the solution immediately before administration. It is recommended to conduct a course of infusions of the drug 2 g 2 times / day for 3-5 days before surgery, and within 1-2 days after surgery.

If it is possible to develop intraoperative ischemia of the extremities , it is recommended to inject 2-4 g of the drug intravenously before surgery, followed by an infusion of 8-10 g in 5% glucose solution during the operation and the reperfusion period.

Special instructions and precautions

Rapid intravenous administration of Daston in high doses (more than 1 g) can cause a drop in blood pressure.

The introduction of the drug in high doses (5-10 g / day) can lead to an increase in the amount of phosphates with a potential effect on calcium metabolism and on the secretion of hormones that regulate homeostasis, kidney function, and purine metabolism. Such doses should only be used in certain rare cases and for short periods.

Influence on the ability to drive vehicles and mechanisms

Reports of the effect of the drug on the ability to drive vehicles and

work with mechanical equipment is not available.

Use during pregnancy and during breastfeeding

Data on the safety and efficacy of the drug during pregnancy and breastfeeding are not available.

As a precautionary measure, it is preferable not to use the drug during pregnancy and during breastfeeding. If the patient is pregnant, planning to become pregnant or breastfeeding, she should inform the doctor about this before using the drug.

Interaction with other drugs

When used as part of complex therapy, phosphocreatine enhances the effectiveness of antiarrhythmic, antianginal drugs, as well as drugs that have a positive effect on the inotropic function of the myocardium.

Side effect

When used according to indications in recommended doses, side effects were not detected.

Perhaps: a decrease in blood pressure with a rapid on / in the introduction.

Overdose

There are no data on cases of drug overdose.

Storage conditions

Store in a dry place below 30°C. Keep out of the reach of children.

Best before date

3 years. Do not use after the expiry date stated on the packaging.

Holiday conditions

Released by prescription.

Release form

1 bottle of 50 ml with instructions for use in a cardboard box.